Efficacy and safety of clofarabine in relapsed and/or refractory non-hodgkin lymphoma, including rituximab-refractory patients

Cancer

Volumn 117, Issue 7, 2011, Pages 1490-1497

  Nabhan, Chadi ^a,b   Davis, Nancy ^b   Bitran, Jacob D ^a,b   Galvez, Angel ^a,b   Fried, Walter ^a,b   Tolzien, Kathy ^a   Foss, Susan ^a   Dewey, Wendy M ^c   Venugopal, Parameswaran ^c  

^a Lutheran General Health Care System   (United States)

^b ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

clofarabine; non Hodgkin lymphoma; refractory lymphoma; relapsed lymphoma; rituximab refractory

Indexed keywords

CLOFARABINE; RITUXIMAB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER RELAPSE; CELLULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEARTBURN; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFECTION; KIDNEY FAILURE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; OVERALL SURVIVAL; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SEIZURE; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URINARY TRACT INFECTION; WEAKNESS;

ADENINE NUCLEOTIDES; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ARABINONUCLEOSIDES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; RETREATMENT; SALVAGE THERAPY;

EID: 79952828602     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25603     Document Type: Article

References (25)

1. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W,. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006; 108: 1504-1508. (Pubitemid 44321768)
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-242. (Pubitemid 34438862)
3. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d′Etude des Lymphomes de l′Adulte. J Clin Oncol. 2005; 23: 4117-4126. (Pubitemid 46211317)
4. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008; 26: 4579-4586.
5. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood. 1988; 71: 117-122. (Pubitemid 18050400)
6. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12: 1169-1176. (Pubitemid 24173930)
7. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin′s lymphoma. N Engl J Med. 1995; 333: 1540-1545.
8. Armitage JO., How I treat patients with diffuse large B-cell lymphoma. Blood. 2007; 110: 29-36. (Pubitemid 47026815)
9. Gribben JG., How I treat indolent lymphoma. Blood. 2007; 109: 4617-4626. (Pubitemid 46830597)
10. Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007; 25: 2554-2559. (Pubitemid 47044812)
11. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998; 92: 1832-1836. (Pubitemid 28406891)
12. Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S., Clofarabine: past, present, and future. Leuk Lymphoma. 2007; 48: 1922-1930. (Pubitemid 47542978)
13. Zhenchuk A, Lotfi K, Juliusson G, Albertioni F., Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009; 78: 1351-1359.
14. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM., The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer. 2005; 103: 1985-1995. (Pubitemid 40605104)
15. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008; 112: 1638-1645.
16. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. 2010; 28: 549-555.
17. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin′s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244-1244.
18. Cancer Therapy Evaluation Program, National Cancer Institute. Common Terminology Criteria for Adverse Events. Accessed July 20, 2010.
19. Blum KA, Hamadani M, Phillips GS, et al. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2009; 50: 349-356.
20. Nabhan C,. Clofarabine in relapsed lymphoma: what is the optimal dose? Leuk Lymphoma. 2009; 50: 1230-1231; author reply 1232-1234.
21. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003; 21: 1167-1173. (Pubitemid 46594149)
22. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin′s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008; 26: 204-210.
23. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010; 116: 106-114.
24. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin′s lymphomas. J Natl Compr Canc Netw. 2010; 8: 288-334.
25. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006; 108: 45-51. (Pubitemid 43990611)